Compugen Ltd.

Wood's flagship Ark Innovation ETF has fallen 54% this year, as her technology companies have stumbled.

Markets don't care about justice, and stocks pass no judgment, says Jim Cramer. But investors do. They should focus on stay-at-home stocks.

Cramer says he's no longer negative on Advanced Micro Devices and thinks Micron Technology is OK.

When you get an unexpected rally, just go with it, Cramer says.

Cramer says Facebook is not expensive, Watsco is a winner and take Regeneron over Compugen.

When the euphoria surrounding Greece fades, Cramer will be watching stocks of companies that have great earnings.

Compugen CGEN was given a "buy" rating with a price target of $17 by analysts at Jefferies Group.

Cramer also likes Verizon and Palo Alto Networks but says Tupperware's last quarter wasn't up to par.

Cramer likes the market but is concerned with what he's seeing with the action on Netflix, LinkedIn and Tesla.

The Federal Reserve meets Wednesday, and the markets could be put to the test, Cramer warned.

Tie-up could bring $540 million for Compugen's cancer immunotherapy treatments.

Compugen's CEO Discusses Q2 2012 Results - Earnings Call Transcript

Regardless of the reason behind it, when a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.

Life-saving companies such as Cerus and Curis could mean life-changing wealth for investors.

Several stocks trading near $5 were moving on above-average volume during Tuesday's session.

Several stocks trading near $5 were poised to move on above-average volume during Tuesday's session.

Several stocks trading near $5 were poised to move on above-average volume during Tuesday's session.

Several stocks trading near $5 were poised to move on above-average volume during Tuesday's session.

A look back at 2009's best- and worst-performing bitoech stocks.

Currently, this is a market primarily for daytraders.

These ARK Funds family funds are focused on new opportunities and investment themes.

The Dublin firm on Nov. 6 unveiled third-quarter numbers that topped analysts' estimates and raised its full-year net sales outlook and the lower end of its 2017 adjusted Ebitda guidance.

Burlington, Mass.-based Flexion Therapeutics said Friday it has receive FDA approval for osteoarthritis knee pain treatment Zilretta, a non-opioid medicine utilizing Flexion's microsphere technology.

Record holiday spending powered a better-than-expected gain for a key retail sales component last month.

Stocks lost ground after a solid opening bell.

The airline launched a dozen new routes to a variety of destinations.